Eastgate Biotech Stock

Eastgate Biotech ROE

The Return on Equity (ROE) of Eastgate Biotech (ETBI) as of Aug 17, 2026 is 64.47 %. In the previous year, Return on Equity (ROE) was 172.56 % — a change of -62.64% (lower).

ROE

64.47 %

YoY

-62.64%

Last updated:

In 2026, Eastgate Biotech's return on equity (ROE) was 64.47 %, a -62.64% increase from the 172.56 % ROE in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Eastgate Biotech Stock analysis

What does Eastgate Biotech do? Eastgate Biotech Corp is a biotechnology company specialized in the development and marketing of natural nutritional products and medicines. The company was founded in Canada in 1999 and is headquartered in Toronto. Eastgate Biotech Corp is listed on the Canadian Securities Exchange and is one of the leading companies in the field of biological medicine. The company's business model is based on the research and development of natural supplements and medicines made from plant and animal ingredients. Eastgate Biotech Corp aims to develop products that improve the well-being of humans and animals and can be manufactured in a natural way. The company relies on the use of innovative technologies and advanced research methods. Eastgate Biotech Corp operates in various sectors including medicine, animal health, and agricultural production. In the field of medicine, the company specializes in the development of medicines for the treatment of various diseases. It uses plant and animal ingredients to create natural remedies. In the animal health sector, Eastgate Biotech Corp offers products specifically designed for the health and well-being of livestock. The company is also involved in agricultural production, offering products that contribute to increasing crop yields. The range of products offered by Eastgate Biotech Corp includes a wide variety of nutritional supplements and medicines. The company offers products that support a healthy diet and help meet the needs for vitamins and minerals. Additionally, Eastgate Biotech Corp offers products that help strengthen the immune system, lower cholesterol levels, or regulate blood pressure. Products for weight control and metabolism support are also available. Some of the most well-known products from Eastgate Biotech Corp include the nutritional supplements "Celergen" and "Deltaweight". "Celergen" is a highly effective preparation that can help increase physical performance, smooth the skin, and improve mental fitness. "Deltaweight" is a nutritional supplement specifically developed for those looking to lose weight or maintain their weight. The product contains a unique blend of natural ingredients that can stimulate metabolism and reduce appetite. Eastgate Biotech Corp has undergone impressive development in recent years and is now one of the leading companies in the field of biological medicine. The company has an experienced team of scientists and experts who support the development of new products. Eastgate Biotech Corp relies on the use of advanced research methods and innovative technologies to manufacture new preparations that can improve the well-being of humans and animals in a natural way. Eastgate Biotech is one of the most popular companies on Eulerpool.

ROE Details

Decoding Eastgate Biotech's Return on Equity (ROE)

Eastgate Biotech's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Eastgate Biotech's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Eastgate Biotech's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Eastgate Biotech’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Eastgate Biotech stock

Return on Equity (ROE) of Eastgate Biotech is 64.47 % in 2026.

Return on Equity (ROE) of Eastgate Biotech changed from 172.56 % to 64.47 %, representing a -62.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Eastgate Biotech since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Eastgate Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Eastgate Biotech

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Eastgate Biotech